- Home
- BYSI vs SKYE Comparison
BYSI vs SKYE Comparison
Compare BYSI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- SKYE
- Stock Information
- Founded
- BYSI 2010
- SKYE 2012
- Country
- BYSI United States
- SKYE United States
- Employees
- BYSI N/A
- SKYE N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- SKYE Health Care
- Exchange
- BYSI Nasdaq
- SKYE Nasdaq
- Market Cap
- BYSI 72.1M
- SKYE 80.7M
- IPO Year
- BYSI 2017
- SKYE N/A
- Fundamental
- Price
- BYSI $1.68
- SKYE $1.81
- Analyst Decision
- BYSI
- SKYE Buy
- Analyst Count
- BYSI 0
- SKYE 6
- Target Price
- BYSI N/A
- SKYE $16.60
- AVG Volume (30 Days)
- BYSI 32.9K
- SKYE 1.7M
- Earning Date
- BYSI 04-14-2022
- SKYE 05-08-2025
- Dividend Yield
- BYSI N/A
- SKYE N/A
- EPS Growth
- BYSI N/A
- SKYE N/A
- EPS
- BYSI N/A
- SKYE N/A
- Revenue
- BYSI N/A
- SKYE N/A
- Revenue This Year
- BYSI N/A
- SKYE N/A
- Revenue Next Year
- BYSI N/A
- SKYE N/A
- P/E Ratio
- BYSI N/A
- SKYE N/A
- Revenue Growth
- BYSI N/A
- SKYE N/A
- 52 Week Low
- BYSI $0.98
- SKYE $1.14
- 52 Week High
- BYSI $3.63
- SKYE $13.49
- Technical
- Relative Strength Index (RSI)
- BYSI 52.97
- SKYE 48.48
- Support Level
- BYSI $1.64
- SKYE $1.36
- Resistance Level
- BYSI $2.14
- SKYE $2.30
- Average True Range (ATR)
- BYSI 0.18
- SKYE 0.21
- MACD
- BYSI 0.03
- SKYE 0.02
- Stochastic Oscillator
- BYSI 44.58
- SKYE 42.35
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.